All In Biotech

Drug Trial Radar · NCT06345482

A Study of MHB039A for Advanced Solid Tumor

A Phase I/II Study of MHB039A for Advanced Solid Tumor to Evaluate the Efficacy and Safety

Last checked: Nov 19, 2026Latest source record: Nov 20, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

196

Planned (sponsor's estimate)

Start

Apr 16, 2024

Primary completion

Apr 1, 2028

Study completion Jun 1, 2029

Sponsor

Sponsor type
Industry
First posted
Apr 3, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Phase I/II open label, multicenter study to evaluate the efficacy and safety of MHB039A in advanced malignant tumors.

Conditions

  • Advanced Solid Tumor

Interventions

  • MHB039ADrug

    a bispecific antibody

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of participants with adverse events (AE)Time frame: Until 30 days after last dose of MHB039A
  2. Number of participants with dose-limiting toxicity (DLT)Time frame: At the end of Cycle 1 (each cycle is 21 days for every three weeks cohort and 28 days for every two weeks cohort)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Shanghai Chest Hospital

    Shanghai, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.